Identification
- Brand Names
- Ultratag
- Generic Name
- Stannous chloride
- DrugBank Accession Number
- DB11056
- Background
Stannous chloride is used as a source of tin in radiopharmaceutical kits. Tin reduces technetium-99m, the active radiological agent, allowing it to form a complex with phosphate-containing moeities 1. These complexes localize primarily in bone (40-50%) and infracted myocardium (0.01-0.02%/g of tissue) allowing for imaging of areas of altered osteogenesis or necrotic heart tissue Label.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Stannous chloride (DB11056)
- Weight
- Average: 189.62
Monoisotopic: 189.839901985 - Chemical Formula
- Cl2Sn
- Synonyms
- Stannous chloride anhydrous
- Stannous chloride,anhydrous
- Tin dichloride
Pharmacology
- Indication
Stannous chloride is a component of technetium-99m agents indicated for imaging of the skeleton for areas of altered osteogenesis or in the detection of infarcted heart tissue Label.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination as diagnostic agent Altered osteogenesis Combination Product in combination with: Technetium Tc-99m pyrophosphate (DB09165) •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Stannous chloride itself is not known to produce a pharmacological effect at the dosages used clinically.
- Mechanism of action
Stannous chloride acts as a reducing agent for technetium-99m allowing formation of a Tc99m-Sn-pyrophosphate complex in combination sodium pyrophosphate 1,Label. See Technetium Tc-99m pyrophosphate for information on the active agent.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Stannous chloride dihydrate 1BQV3749L5 10025-69-1 GATSHYKZJFLTJA-UHFFFAOYSA-L - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Ultratag RBC Injection, powder, lyophilized, for solution; Kit 0.05 mg/9.5mg Intravenous Curium US LLC 1991-06-10 Not applicable US 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image High Potency Multivitamins & Minerals Caplets Stannous chloride (0.01 mg) + Ascorbic acid (100 mg) + Beta carotene (2500 unit) + Biotin (45 mcg) + Calcium phosphate, dibasic (125 mg) + Calcium Phosphate (175 mg) + Cholecalciferol (400 unit) + Chromic chloride (50 mcg) + Cupric sulfate (2 mg) + Cyanocobalamin (9 mcg) + Ferrous fumarate (10 mg) + Folic acid (0.4 mg) + Magnesium oxide (100 mg) + Manganese sulfate (5 mg) + Nickel sulfate (5 mcg) + Nicotinamide (40 mg) + Pantothenic acid (10 mg) + Potassium Iodide (0.15 mg) + Potassium chloride (50 mg) + Potassium chloride (55 mg) + Pyridoxine hydrochloride (4 mg) + Riboflavin (3.4 mg) + Sodium selenate (50 mcg) + Silicon dioxide (0.01 mg) + Sodium metavanadate (10 mcg) + Sodium molybdate (50 mcg) + Thiamine mononitrate (3 mg) + Vitamin A acetate (3500 unit) + Zinc citrate (20 mg) + alpha-Tocopherol acetate (50 unit) Tablet Oral Ashbury Research Corporation Not applicable Not applicable Canada 
Multivitamins and Minerals Tablets Stannous chloride (0.010 mg) + Ascorbic acid (120 mg) + Beta carotene (1000 unit) + Biotin (40 mcg) + Calcium (162 mg) + Calcium Phosphate (125 mg) + Cholecalciferol (400 unit) + Chromic chloride (120 mcg) + Cupric sulfate (2 mg) + Cyanocobalamin (18 mcg) + Ferrous fumarate (15 mg) + Folic acid (0.4 mg) + Magnesium (50 mg) + Manganese (4 mg) + Nickel sulfate (5 mcg) + Nicotinamide (40 mg) + Calcium pantothenate (10 mg) + Potassium (80 mg) + Potassium Iodide (0.150 mg) + Potassium chloride (72 mg) + Pyridoxine hydrochloride (6 mg) + Riboflavin (5.1 mg) + Sodium selenite (70 mcg) + Silicon (4 mg) + Sodium metavanadate (10 mcg) + Sodium molybdate (50 mcg) + Thiamine mononitrate (4.5 mg) + Vitamin A (4000 unit) + Zinc (15 mg) + alpha-Tocopherol acetate (60 unit) Tablet Oral Pharmetics (2011) Inc. 2004-06-03 2009-07-30 Canada Spectrum Performa Multivitamins and Minerals Tablets Stannous chloride (0.01 mg) + Ascorbic acid (120 mg) + Beta carotene (1000 unit) + Biotin (40 mcg) + Calcium (162 mg) + Calcium Phosphate (125 mg) + Cholecalciferol (400 unit) + Chromic chloride (120 mcg) + Cupric sulfate (2 mg) + Cyanocobalamin (18 mcg) + Ferrous fumarate (18 mg) + Folic acid (0.4 mg) + Magnesium (50 mg) + Manganese (4 mg) + Nickel sulfate (5 mcg) + Nicotinamide (40 mg) + Calcium pantothenate (10 mg) + Potassium (80 mg) + Potassium Iodide (0.15 mg) + Potassium chloride (72 mg) + Pyridoxine hydrochloride (6 mg) + Riboflavin (5.1 mg) + Sodium selenite (70 mcg) + Silicon (4 mg) + Sodium metavanadate (10 mcg) + Sodium molybdate (50 mcg) + Thiamine mononitrate (4.5 mg) + Vitamin A (4000 unit) + Zinc (15 mg) + alpha-Tocopherol acetate (60 unit) Tablet Oral Pharmetics (2011) Inc. 2003-03-12 2009-07-30 Canada Technescan PYP Stannous chloride dihydrate (3.2 mg/10mL) + Sodium pyrophosphate (11.9 mg/10mL) Injection, powder, lyophilized, for solution Intravenous Curium US LLC 2015-10-14 Not applicable US Technescan PYP Stannous chloride dihydrate (3.2 mg/10mL) + Technetium Tc-99m pyrophosphate (11.9 mg/10mL) Injection, powder, lyophilized, for solution Intravenous Mallinckrodt 2009-03-20 2017-07-01 US
Categories
- Drug Categories
- Not Available
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as post-transition metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is a post-transition metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Post-transition metal salts
- Sub Class
- Post-transition metal chlorides
- Direct Parent
- Post-transition metal chlorides
- Alternative Parents
- Inorganic tin salts / Inorganic chloride salts
- Substituents
- Inorganic chloride salt / Inorganic salt / Inorganic tin salt / Post-transition metal chloride
- Molecular Framework
- Not Available
- External Descriptors
- inorganic chloride, tin molecular entity (CHEBI:78067)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- R30H55TN67
- CAS number
- 7772-99-8
- InChI Key
- AXZWODMDQAVCJE-UHFFFAOYSA-L
- InChI
- InChI=1S/2ClH.Sn/h2*1H;/q;;+2/p-2
- IUPAC Name
- lambda2-tin(2+) dichloride
- SMILES
- [Cl-].[Cl-].[Sn++]
References
- General References
- Thrall JH: Technetium-99m labeled agents for skeletal imaging. CRC Crit Rev Clin Radiol Nucl Med. 1976;8(1):1-31. [Article]
- External Links
- ChemSpider
- 22887
- 314853
- ChEBI
- 78067
- Wikipedia
- Tin(II)_chloride
- FDA label
- Download (105 KB)
- MSDS
- Download (50.4 KB)
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral Tablet Oral Injection, powder, lyophilized, for solution Intravenous Kit Injection, powder, lyophilized, for solution; kit Intravenous 0.05 mg/9.5mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 38 MSDS water solubility Freely soluble MSDS - Predicted Properties
Property Value Source Water Solubility 65.4 mg/mL ALOGPS logP 0.66 ALOGPS logP 0.61 Chemaxon logS -0.46 ALOGPS pKa (Strongest Acidic) -7 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 5.62 m3·mol-1 Chemaxon Polarizability 2.39 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at December 03, 2015 16:51 / Updated at February 13, 2021 11:02